KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures (2016 - 2018)

Teva Pharmaceutical Industries filings provide 6 years of Gains from Sales and Divestitures readings, the most recent being $1.6 million for Q4 2018.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $1.6 million in Q4 2018 year-over-year; TTM through Dec 2018 was $1.6 million, a N/A change, with the full-year FY2018 number at $1.6 million, changed N/A from a year prior.
  • Gains from Sales and Divestitures hit $1.6 million in Q4 2018 for Teva Pharmaceutical Industries, up from $830000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.6 million in Q4 2018 to a low of -$1.1 million in Q4 2015.
  • Median Gains from Sales and Divestitures over the past 4 years was $988000.0 (2014), compared with a mean of $625500.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 197.03% in 2015 and later skyrocketed 174.64% in 2016.
  • Teva Pharmaceutical Industries' Gains from Sales and Divestitures stood at $1.1 million in 2014, then tumbled by 197.03% to -$1.1 million in 2015, then skyrocketed by 174.64% to $830000.0 in 2016, then soared by 97.35% to $1.6 million in 2018.
  • The last three reported values for Gains from Sales and Divestitures were $1.6 million (Q4 2018), $830000.0 (Q4 2016), and -$1.1 million (Q4 2015) per Business Quant data.